Key Performance
More- Earnings Score: N/A
- Momentum Score: 67
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
E.F. Hutton & Co. served as exclusive financial advisor and placement agent for a strategic business combination between Glucotrack, Inc. and Lōkahi Therapeutics, along with a $5.7 million convertible note financing. The transaction creates a publicly traded healthcare platform combining Lōkahi's AI-driven asset sourcing capabilities with Glucotrack's Nasdaq listing, with Lōkahi becoming the operating company and Glucotrack's CBGM business continuing as a subsidiary.
07/17/2026, 1:20 PM • GlobeNewswire
Glucotrack, Inc. (NASDAQ: GCTK) completed a strategic business combination with Lōkahi Therapeutics, creating a publicly listed platform for identifying and advancing healthcare assets. Lōkahi Therapeutics securityholders will hold approximately 90% of the combined company on a fully diluted basis. Erik Emerson was appointed CEO, while Glucotrack's continuous blood glucose monitoring (CBGM) technology will operate as a separate subsidiary under Paul Goode's leadership. The transaction is supported by a planned private placement financing.
07/16/2026, 4:57 PM • GlobeNewswire
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Glucotrack Inc. (NASDAQ: GCTK) submitted an Investigational Device Exemption (IDE) application to the FDA for its fully implantable continuous blood glucose monitoring (CBGM) technology, targeting U.S. clinical trial launch in H2 2026. The company reported Q1 2026 net loss of $4.3 million versus $6.8 million in Q1 2025, with cash position of $3.9 million as of March 31, 2026. Two peer-reviewed studies supporting the technology's long-term stability and accuracy were published, and the company reduced debt while strengthening its balance sheet.
05/14/2026, 5:27 PM • GlobeNewswire
Glucotrack, Inc. (NASDAQ: GCTK) announced the submission of its Investigational Device Exemption (IDE) application to the FDA to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology. The submission follows years of preclinical development and represents a significant milestone toward clinical evaluation and potential regulatory approval of the long-term implantable glucose monitoring system designed for people with diabetes.
05/07/2026, 1:00 PM • GlobeNewswire
Glucotrack reported full year 2025 net loss of $19.4 million, an improvement from $22.6 million in 2024. The company completed a $4.0 million private placement, received three new USPTO patents for its implantable continuous blood glucose monitoring technology, and plans to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 to launch U.S. clinical trials in the second half of 2026. Cash position improved to $7.4 million from $5.6 million year-over-year.
03/30/2026, 4:50 PM • GlobeNewswire
